Labeled for this condition
Medicines for crohn's disease and ulcerative colitis
29 medicines have an FDA label indicated for crohn's disease and ulcerative colitis; 11 are listed from generic labelers and 2 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for crohn's disease and ulcerative colitis?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Hydrocortisone | Solu-Cortef, Alkindi, Cortef | 49 labelers | $0.0613 per gram 1% cream | No | A presentation being discontinued | 7 |
| Prednisone | none listed | 45 labelers | $0.0643 per tablet 20 mg tablet | No | No current entry | 10 |
| Dexamethasone | Ozurdex, Maxidex, Hemady | 60 labelers | $0.193 per tablet 4 mg tablet | No | In shortage | 8 |
| Methylprednisolone | Solu-Medrol, Depo-Medrol, Medrol | 35 labelers | $0.121 per tablet 4 mg tablet | No | In shortage | 46 |
| Budesonide | Pulmicort, Uceris, Eohilia | 30 labelers | $0.498 per capsule 3 mg capsule | No | No current entry | 9 |
| Mesalamine | Pentasa, Canasa, Rowasa | 34 labelers | $0.781 per tablet 1.2 g tablet | No | A presentation being discontinued | 6 |
| Adalimumab | Amjevita, Humira, Hyrimoz | none listed | $1,587.82 per mL 40 mg/0.4 mL | Yes | No current entry | 1 |
| Prednisolone | Orapred, Pred | 25 labelers | $4.72 per mL 1% eye drop | No | No current entry | 9 |
| Tofacitinib | Xeljanz | 24 labelers | $0.573 per tablet 5 mg tablet | Yes | No current entry | 0 |
| Ustekinumab | Wezlana, Pyzchiva, Steqeyma | none listed | $29,874.45 per mL 45 mg/0.5 mL syringe | No | No current entry | 0 |
| Adalimumab-adbm | Cyltezo | none listed | $639.19 per pen 40 mg/0.4 mL | Yes | No current entry | 0 |
| Sulfasalazine | Azulfidine | 5 labelers | $0.199 per tablet 500 mg tablet | No | No current entry | 0 |
| Adalimumab-ryvk | Simlandi | none listed | $499.12 per unit 40 mg/0.4 mL autoinjector | Yes | A presentation being discontinued | 0 |
| Risankizumab | Skyrizi | none listed | $22,774.36 per mL 150 mg/mL pen | No | No current entry | 0 |
| Balsalazide | none listed | 9 labelers | $0.344 per capsule 750 mg capsule | No | No current entry | 0 |
| Ustekinumab-aekn | Selarsdi | none listed | n/a | No | No current entry | 0 |
| Adalimumab-aaty | Yuflyma | none listed | $495.75 per unit 40 mg/0.4 mL autoinjector | Yes | No current entry | 0 |
| Adalimumab-afzb | Abrilada | none listed | n/a | Yes | A presentation being discontinued | 0 |
| Adalimumab-fkjp | Hulio | none listed | n/a | Yes | No current entry | 0 |
| Infliximab | Remicade, Inflectra, Renflexis | none listed | n/a | Yes | No current entry | 2 |
| Cortisone | none listed | 1 labeler | n/a | No | No current entry | 0 |
| Upadacitinib | Rinvoq | none listed | $229.31 per tablet 15 mg tablet | Yes | No current entry | 0 |
| Certolizumab | Cimzia | none listed | $6,094.02 per syringe 2x200 mg/mL syringe kit | Yes | No current entry | 1 |
| Golimumab | Simponi | none listed | $12,890.32 per mL 50 mg/0.5 mL pen injec | Yes | No current entry | 0 |
| Guselkumab | Tremfya | none listed | $14,728.91 per mL 100 mg/mL syringe | No | No current entry | 1 |
| Ustekinumab-srlf | Imuldosa | none listed | n/a | No | No current entry | 1 |
| Adalimumab-aacf | Idacio | none listed | n/a | Yes | No current entry | 0 |
| Etrasimod arginine | Velsipity | none listed | n/a | No | No current entry | 0 |
| Olsalazine | Dipentum | none listed | $15.70 per capsule 250 mg capsule | No | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price